FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1989720897> ?p ?o ?g. }

• W1989720897 endingPage "277" @default.
• W1989720897 startingPage "274" @default.
• W1989720897 abstract "Pemetrexed maintenance therapy significantly improved overall survival and progression-free survival compared with placebo, and had a good safety profile in a phase 3 placebo-controlled study in patients with advanced non-small-cell lung cancer (NSCLC). Results for quality of life, symptom palliation, and tolerability are presented here.After four cycles of platinum-based induction therapy, 663 patients with stage IIIB or stage IV NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (in a 2:1 ratio) from March 15, 2005, to July 20, 2007, using the Pocock and Simon minimisation method to receive pemetrexed (500 mg/m2 every 21 days; n=441) or placebo (n=222) plus best supportive care until disease progression. The primary efficacy data have been reported previously. Patients completed the Lung Cancer Symptom Scale (LCSS) at baseline, after each cycle, and post-discontinuation. Worsening of symptoms was defined as an increase of 15 mm or more from baseline on a 100 mm scale for each LCSS item. The primary outcome for these quality-of-life analyses was time to worsening of symptoms, analysed for all randomised patients. This study is registered with ClinicalTrials.gov, number NCT00102804.Baseline characteristics, including LCSS scores, were well balanced between groups. Baseline LCSS scores were low, indicating low symptom burden for patients without disease progression after completion of first-line treatment. Longer time to worsening was recorded for pain (hazard ratio [HR] 0·76, 95% CI 0·59–0·99; p=0·041) and haemoptysis (HR 0·58, 95% CI 0·34–0·97; p=0·038) with pemetrexed than with placebo; no other significant differences in analyses of time to worsening were noted. Additional longitudinal analyses showed a greater increase in loss of appetite in the pemetrexed group than in the placebo group (4·3 mm vs 0·2 mm; p=0·028). Rates of resource use were statistically higher for pemetrexed than for placebo: admissions to hospital for drug-related adverse events (19 [4%] vs none; p=0·001), transfusions (42 [10%] vs seven [3%]; p=0·003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0·017).Quality of life during maintenance therapy with pemetrexed is similar to placebo, except for a small increase in loss of appetite, and significantly delayed worsening of pain and haemoptysis. In view of the improvements in overall and progression-free survival noted with pemetrexed maintenance therapy, such treatment is an option for patients with advanced non-squamous NSCLC who have not progressed after platinum-based induction therapy.Eli Lilly." @default.
• W1989720897 created "2016-06-24" @default.
• W1989720897 creator A5072257104 @default.
• W1989720897 date "2005-11-01" @default.
• W1989720897 modified "2023-09-24" @default.
• W1989720897 title "Overview and Introduction" @default.
• W1989720897 cites W145406579 @default.
• W1989720897 cites W1966281978 @default.
• W1989720897 cites W2039874252 @default.
• W1989720897 cites W2068141984 @default.
• W1989720897 cites W2126908748 @default.
• W1989720897 cites W2328027428 @default.
• W1989720897 cites W2334360477 @default.
• W1989720897 cites W3147566403 @default.
• W1989720897 cites W70178239 @default.
• W1989720897 doi "https://doi.org/10.1016/j.currproblcancer.2005.09.001" @default.
• W1989720897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16311128" @default.
• W1989720897 hasPublicationYear "2005" @default.
• W1989720897 type Work @default.
• W1989720897 sameAs 1989720897 @default.
• W1989720897 citedByCount "10" @default.
• W1989720897 countsByYear W19897208972012 @default.
• W1989720897 crossrefType "journal-article" @default.
• W1989720897 hasAuthorship W1989720897A5072257104 @default.
• W1989720897 hasConcept C126322002 @default.
• W1989720897 hasConcept C141071460 @default.
• W1989720897 hasConcept C142724271 @default.
• W1989720897 hasConcept C143998085 @default.
• W1989720897 hasConcept C146357865 @default.
• W1989720897 hasConcept C151730666 @default.
• W1989720897 hasConcept C159110408 @default.
• W1989720897 hasConcept C168563851 @default.
• W1989720897 hasConcept C197934379 @default.
• W1989720897 hasConcept C204787440 @default.
• W1989720897 hasConcept C207103383 @default.
• W1989720897 hasConcept C27081682 @default.
• W1989720897 hasConcept C2776256026 @default.
• W1989720897 hasConcept C2776694085 @default.
• W1989720897 hasConcept C2776907518 @default.
• W1989720897 hasConcept C2777240266 @default.
• W1989720897 hasConcept C2778239845 @default.
• W1989720897 hasConcept C2778375690 @default.
• W1989720897 hasConcept C2778715236 @default.
• W1989720897 hasConcept C2779951463 @default.
• W1989720897 hasConcept C44249647 @default.
• W1989720897 hasConcept C71924100 @default.
• W1989720897 hasConcept C86803240 @default.
• W1989720897 hasConceptScore W1989720897C126322002 @default.
• W1989720897 hasConceptScore W1989720897C141071460 @default.
• W1989720897 hasConceptScore W1989720897C142724271 @default.
• W1989720897 hasConceptScore W1989720897C143998085 @default.
• W1989720897 hasConceptScore W1989720897C146357865 @default.
• W1989720897 hasConceptScore W1989720897C151730666 @default.
• W1989720897 hasConceptScore W1989720897C159110408 @default.
• W1989720897 hasConceptScore W1989720897C168563851 @default.
• W1989720897 hasConceptScore W1989720897C197934379 @default.
• W1989720897 hasConceptScore W1989720897C204787440 @default.
• W1989720897 hasConceptScore W1989720897C207103383 @default.
• W1989720897 hasConceptScore W1989720897C27081682 @default.
• W1989720897 hasConceptScore W1989720897C2776256026 @default.
• W1989720897 hasConceptScore W1989720897C2776694085 @default.
• W1989720897 hasConceptScore W1989720897C2776907518 @default.
• W1989720897 hasConceptScore W1989720897C2777240266 @default.
• W1989720897 hasConceptScore W1989720897C2778239845 @default.
• W1989720897 hasConceptScore W1989720897C2778375690 @default.
• W1989720897 hasConceptScore W1989720897C2778715236 @default.
• W1989720897 hasConceptScore W1989720897C2779951463 @default.
• W1989720897 hasConceptScore W1989720897C44249647 @default.
• W1989720897 hasConceptScore W1989720897C71924100 @default.
• W1989720897 hasConceptScore W1989720897C86803240 @default.
• W1989720897 hasIssue "6" @default.
• W1989720897 hasLocation W19897208971 @default.
• W1989720897 hasLocation W19897208972 @default.
• W1989720897 hasOpenAccess W1989720897 @default.
• W1989720897 hasPrimaryLocation W19897208971 @default.
• W1989720897 hasRelatedWork W2013653877 @default.
• W1989720897 hasRelatedWork W2027821191 @default.
• W1989720897 hasRelatedWork W2130808260 @default.
• W1989720897 hasRelatedWork W2358450743 @default.
• W1989720897 hasRelatedWork W2606568050 @default.
• W1989720897 hasRelatedWork W2768988395 @default.
• W1989720897 hasRelatedWork W3011176692 @default.
• W1989720897 hasRelatedWork W3029430426 @default.
• W1989720897 hasRelatedWork W3140001506 @default.
• W1989720897 hasRelatedWork W4254666574 @default.
• W1989720897 hasVolume "29" @default.
• W1989720897 isParatext "false" @default.
• W1989720897 isRetracted "false" @default.
• W1989720897 magId "1989720897" @default.
• W1989720897 workType "article" @default.